High-Dose favipiravir safety trial launches in healthy volunteers
NCT ID NCT06024421
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 study is testing whether high doses of the antiviral drug favipiravir are safe and tolerable in healthy volunteers. About 39 participants will receive either favipiravir or a placebo for 14 days, with doses increasing in three groups. Researchers will also measure drug levels in blood and sperm, and look at genetic factors that might affect how the drug is processed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- favipiravir
- What this could lead to
- If successful, this could help determine safe high doses of favipiravir for future studies in infectious diseases.
- What could go wrong
- This is an early Phase 1 trial with only 39 healthy volunteers, so results may not apply to patients. High doses may cause side effects not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Bichat - Claude Bernard
RECRUITINGParis, 75018, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Leftover blood samples could unlock new medical discoveries
- La reunion health survey aims to uncover hidden disease patterns
- Hunting the genes that make severe infections worse
- Aging immune system under the microscope: study seeks clues to infection risk in seniors
- New DNA test could revolutionize diagnosis of eye infections
- New mRNA vaccine aims to shield older adults from RSV